Tiantan Biological (600161.SH) subsidiary obtains clinical trial summary report for human coagulation factor IX

Zhitong Finance APP news, Tiantan Biological (600161.SH) announced that recently, "Human Coagulation Factor IX" developed by its subsidiary Chengdu Rongsheng Pharmaceutical Co., Ltd. (referred to as "Chengdu Rongsheng") completed Phase III clinical trials and obtained the clinical trial summary report.